Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
Goldberg L, Yoon J, Johnston H, Davidson M, Siddon A, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Kassner J, Rampal R, Guru Murthy G, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Odenike O, Cursio J, Patel A. Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors. Blood 2024, 144: 1787-1787. DOI: 10.1182/blood-2024-197898.Peer-Reviewed Original ResearchIsocitrate dehydrogenase inhibitorsMedian OSMPN-AP/BPIntensive chemotherapyMyeloproliferative neoplasmsHypomethylating agentsEuropean LeukemiaNetAcute myeloid leukemiaMPN-BPComplete remissionOverall survivalCytogenetic responsePartial remissionBlast phaseTen ptsCo-mutationsIncidence of driver mutationsVariable risk of progressionAchievement of complete remissionAllogeneic stem cell transplantationAssociated with poor overall survivalCohort of ptsIDH1 inhibitor ivosidenibIDH2 inhibitor enasidenibIncomplete count recovery